<DOC>
	<DOC>NCT01297569</DOC>
	<brief_summary>This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to diabetic macular edema.</brief_summary>
	<brief_title>Ranibizumab "Treat and Extend" in Diabetic Macular Edma</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual impairment due to focal or diffuse macular edema with center involvement Diabetes type 1 or 2, HbA1c &lt; 12.0% CRT = or &gt; 250 Î¼m Active inflammation or infection Uncontrolled glaucoma Iris neovascularization, active proliferative retinopathy or vitreomacular traction Prior laser photocoagulation according to defined timelines History of stroke, uncontrolled hypertension Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Macular edema</keyword>
	<keyword>DME</keyword>
	<keyword>Diabetic retinopathy</keyword>
	<keyword>Diabetic eye disease</keyword>
	<keyword>anti-VEGF</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>Lucentis</keyword>
</DOC>